Dr Naval Daver from The University of Texas MD Anderson Cancer Center discusses optimizing the management of acute myeloid leukemia and myelodysplastic syndromes. Topics include the productivity of researchers in leukemia, the potential of checkpoint inhibitors, challenges of managing TP53 mutated disease, various drug therapies for AML and MDS, management of qtc prolongation, combination therapy, and the continuation of Van Aza treatment.

Naval Daver and Paresh Vyas discuss mechanisms of resistance to targeted therapies in AML, including the impact of small clones and non-cell intrinsic effects. They explore the modulation of leukemia by therapies and the potential of using companion diagnostics and immunotherapies to predict long-term responders. The podcast also highlights the importance of testing for flip three mutation in AML patients and the role of epigenetic targets in therapy resistance.

Naval Daver from MD Anderson Cancer Center leads an exciting discussion on the latest updates in the use of venetoclax-based regimens for the treatment of AML. Topics include the potential of azocididine and Venetoclax combination as a new standard of care, safety and feasibility of combination treatments, comparing regimens for AML patients, the dilemma of induction therapy, and ongoing studies and future directions in hematology.